EGFR and glioblastoma: Perhaps the most striking finding, especially in the GBM modelling context, was that glioma PDCs, unlike the majority of 2D systems, retain genomic alterations in EGFR such as amplification, mutation, or deletion of exons 2–7 (EGFRvIII).